<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name>ООО «Издательство "Открытые системы"»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2023.26.2.013</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1052</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНАЯ ТЕМА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TOPICAL THEME</subject></subj-group></article-categories><title-group><article-title>Выявление антител, ассоциированных с антифосфолипидным синдромом, у больных сифилисом</article-title><trans-title-group xml:lang="en"><trans-title>Detection of antibodies associated with anti-phospholipid syndrome in patients with syphilis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3856-957X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левчик</surname><given-names>Н. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Levchik</surname><given-names>N. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Левчик Надежда Константиновна, к.м.н., доцент, заведующая научным клиническим отделом сифилидологии и инфекций, передающихся половым путем</p><p>620076, Екатеринбург, ул. Щербакова, 8</p></bio><bio xml:lang="en"><p>Nadezhda K. Levchik, MD, Associate professor, Head of the Clinical department of syphilidology and sexually transmitted infections</p><p>620076, Yekaterinburg, Shcherbakova str., 8</p></bio><email xlink:type="simple">nklevchik@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7407-7575</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зильберберг</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zilberberg</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зильберберг Наталья Владимировна, д.м.н., профессор, заместитель директора по научной работе</p><p>620076, Екатеринбург, ул. Щербакова, 8</p></bio><bio xml:lang="en"><p>Nataliya V. Zilberberg, Dr. of Sci. (Med.), Professor, Deputy Director</p><p>620076, Yekaterinburg, Shcherbakova str., 8</p></bio><email xlink:type="simple">zilberberg@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0409-9856</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пономарева</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ponomareva</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пономарева Марина Владиславовна, к.б.н., старший научный сотрудник научного экспериментально-лабораторного отдела</p><p>620076, Екатеринбург, ул. Щербакова, 8</p></bio><bio xml:lang="en"><p>Marina V. Ponomareva, Cand. of Sci. (Biol.), Senior researcher at the Department of laboratory medicine</p><p>620076, Yekaterinburg, Shcherbakova str., 8</p></bio><email xlink:type="simple">marpo08@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственное бюджетное учреждение Свердловской области Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Budgetary Institution of the Sverdlovsk Region Ural Research Institute of Dermatology, Venereology and Immunopathology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>19</day><month>04</month><year>2023</year></pub-date><volume>0</volume><issue>2</issue><fpage>86</fpage><lpage>91</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Левчик Н.К., Зильберберг Н.В., Пономарева М.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Левчик Н.К., Зильберберг Н.В., Пономарева М.В.</copyright-holder><copyright-holder xml:lang="en">Levchik N.K., Zilberberg N.V., Ponomareva M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1052">https://journal.lvrach.ru/jour/article/view/1052</self-uri><abstract><p>В связи с недостатком сведений об антителах, ассоциированных с антифосфолипидным синдромом при сифилисе, предпринято изучение закономерностей продукции антител при сифилитической инфекции. Уровень антифосфолипидных антител был измерен у 394 больных с различными формами сифилиса, из которых 85 человек находились под динамическим наблюдением. Включенные в исследование пациенты имели полноценные анамнестические данные, соответствовавшие всем необходимым диагностическим критериям, и прошли все виды клинико-лабораторного обследования для установления диагноза. Для выявления использовали наборы ThromboCombo IgG/IgM ELISA Kit, Anti-Cardiolipin Screen, Anti-Cardiolipin ELISA (IgAGM), Anti-β2-Glycoprotein 1 ELISA (IgAMG). Пороговые значения для положительных результатов были определены на основе рекомендаций производителя. Сравнения качественных признаков проводились с помощью критериев Хи-квадрат (χ2) или Фишера, количественных – t-критерия или U-критерия Манна – Уитни, с корректировкой уровня значимости для выявления существенно различных пар при множественном сравнении с помощью процедуры Бонферрони. Для сравнения количественных признаков в связанных выборках использовали парный t-критерий или критерий Уилкоксона. Для оценки связи применяли метод ранговой корреляции Спирмена. Антитела к кардиолипину встречались с наибольшей частотой у больных вторичным сифилисом (81%), причем их частота была значительно выше при первичном (49%) и раннем скрытом (52%) сифилисе по сравнению с поздним скрытым сифилисом (18%), нейросифилисом (15%) и состоянием серорезистентности (17%). Уровень антител к кардиолипину снижался у больных ранним сифилисом вскоре после начала лечения и сохранялся годами на низких значениях без изменений у больных поздним сифилисом. Доля пациентов с положительным тестом на антитела к бета-2-гликопротеину 1 существенно не отличалась при всех формах сифилиса (13-21%). У больных сифилисом не было выявлено значимого иммунного ответа на фосфатидилсерин, фосфатидилинозитол, фосфатидную кислоту. Антитела к кардиолипину могут играть роль в развитии осложнений на ранних стадиях сифилиса и быть полезными для ранней диагностики сифилиса и реинфекции, а также для дифференциальной диагностики ранних и поздних форм. Скрининг на сифилис рекомендуется лицам с первым эпизодом повышения уровня антител к кардиолипину. </p></abstract><trans-abstract xml:lang="en"><p>Little is known about the behavior of antibodies associated with anti-phospholipid syndrome in syphilis. To investigate the patterns of antibodies associated with anti-phospholipid syndrome production in syphilitic infection. The serum level of anti-phospholipid antibodies was measured in 394 patients with different forms of syphilis, 85 of which were followed after treatment. The patients included in the study had complete anamnestic data that met all the necessary diagnostic criteria, and underwent all types of clinical and laboratory examinations to establish the diagnosis. To detect anti-bodies the ThromboCombo IgG/IgM ELISA Kit, Anti-Cardiolipin Screen, Anti-Cardiolipin ELISA (IgAGM), Anti-β2-Glycoprotein 1 ELISA (IgAMG) were used. The cut-off values for positive results were determined based on the manufacturer's recommendations. Comparisons of qualitative features were carried out using the chi-squared test (χ2) or Fisher tests, quantitative – t-test or Mann – Whitney U-test, with the level of significance adjusted to identify significantly different pairs in multiple comparisons using the Bonferroni procedure. The paired t-test or the Wilcoxon test was used to compare quantitative traits in related samples. Spearman's rank correlation method was used to assess the relationship. Anti-cardiolipin antibodies occurred with the greatest frequency in patients with secondary syphilis (81%). The frequency of anti-cardiolipin antibodies was significantly higher in primary (49%) and early latent (52%) syphilis compared with late latent syphilis (18%), neurosyphilis (15%) and serofast state (17%). The anti-cardiolipin antibodies level decreased shortly after initiation of treatment in patients with early syphilis, and lasted years at low values without changes in patients with late syphilis. The proportion of patients testing positive for beta-2-glycoprotein I antibodies did not differ significantly in all forms of syphilis (13-21%). No significant antibody response to phosphatidyl serine, phosphatidyl inositol, phosphatidic acid was observed in the patients with syphilis. Anti-cardiolipin antibodies may play a role in the development of complications in early stage syphilis and have utility in early diagnosis of syphilis, diagnosis of reinfection, and differential diagnosis of early and late forms. The screening for syphilis is recommend in subjects with first-episode of raised level of anti-cardiolipin antibodies.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сифилис</kwd><kwd>Treponema pallidum</kwd><kwd>аутоиммунные антитела</kwd><kwd>антитела к кардиолипину</kwd><kwd>антитела к бета-2- гликопротеину 1</kwd><kwd>антифосфолипидный синдром</kwd><kwd>бактериальная инфекция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>syphilis</kwd><kwd>Treponema pallidum</kwd><kwd>anti-cardiolipin antibodies</kwd><kwd>anti-β2 glycoprotein 1 antibodies</kwd><kwd>autoimmune antibodies</kwd><kwd>antiphospholipid syndrome</kwd><kwd>bacterial infection</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bradacova P., Slavik L., Ulehlova J., et al. Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review // Biomedicines. 2021; 8; 9 (2): 166.</mixed-citation><mixed-citation xml:lang="en">Bradacova P., Slavik L., Ulehlova J., et al. Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review // Biomedicines. 2021; 8; 9 (2): 166.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Shen X., Liu D., Lin Y., et al. The characteristics of beta 2-glycoprotein I-dependent anticardiolipin antibody and blood coagulation status in subjects with classical biological false-positive syphilis reactions // I. immunopharmacology. 2018; 62: 132-138.</mixed-citation><mixed-citation xml:lang="en">Shen X., Liu D., Lin Y., et al. The characteristics of beta 2-glycoprotein I-dependent anticardiolipin antibody and blood coagulation status in subjects with classical biological false-positive syphilis reactions // I. immunopharmacology. 2018; 62: 132-138.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bernard C., de Moerloose P., Tremblet C., et al. Biological true and false serological tests for syphilis: Their relationship with anticardiolipin antibodies // Dermatologica. 1990; 180: 151-153.</mixed-citation><mixed-citation xml:lang="en">Bernard C., de Moerloose P., Tremblet C., et al. Biological true and false serological tests for syphilis: Their relationship with anticardiolipin antibodies // Dermatologica. 1990; 180: 151-153.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Loizou S., Singh S., Wypkema E., et al. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease // Ann Rheum Dis. 2003; 62 (11): 1106-1111.</mixed-citation><mixed-citation xml:lang="en">Loizou S., Singh S., Wypkema E., et al. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease // Ann Rheum Dis. 2003; 62 (11): 1106-1111.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">McNally T., Purdy G., Mackie I. J., et al.: The use of an anti-b2- glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis // Br J Haematol. 1995; 91: 471-473.</mixed-citation><mixed-citation xml:lang="en">McNally T., Purdy G., Mackie I. J., et al.: The use of an anti-b2- glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis // Br J Haematol. 1995; 91: 471-473.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Santiago M., Martinelli R., Ko A., et al. Anti- 2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar // Clin Exp Rheumatol. 2001; 19: 425-430.</mixed-citation><mixed-citation xml:lang="en">Santiago M., Martinelli R., Ko A., et al. Anti- 2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar // Clin Exp Rheumatol. 2001; 19: 425-430.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Santiago M., Stellin R., Gaburo Júnior N., et al. Antiphospholipid antibodies in syphilis // Braz J Med Biol Res. 1990; 23 (5): 397-402.</mixed-citation><mixed-citation xml:lang="en">Santiago M., Stellin R., Gaburo Júnior N., et al. Antiphospholipid antibodies in syphilis // Braz J Med Biol Res. 1990; 23 (5): 397-402.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">De Larranaga G. F., Forastiero R. R., Carreras L. O., et al. Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome // Thromb Res. 1999; 96: 19-25.</mixed-citation><mixed-citation xml:lang="en">De Larranaga G. F., Forastiero R. R., Carreras L. O., et al. Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome // Thromb Res. 1999; 96: 19-25.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Levy R. A., de Meis E., Pierangeli S. An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay // Thromb. Res. 2004; 114: 573-577.</mixed-citation><mixed-citation xml:lang="en">Levy R. A., de Meis E., Pierangeli S. An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay // Thromb. Res. 2004; 114: 573-577.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Левчик Н. К., Зильберберг Н. В., Пономарева М. В., Белых О. А. Сифилитическая инфекция: исследование врожденных гуморальных факторов иммунного ответа // Лечащий Врач. 2022; 4 (25): 33-37.</mixed-citation><mixed-citation xml:lang="en">Levchik N. K., Zilberberg N. V., Ponomareva M. V., Belykh O. A. Syphilitic infection: a study on the factors of the innate humoral immune response // Lechaschi Vrach. 2022; 4 (25): 33-37.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gwynne P. J., Clendenen L. H., Turk S. P., et al. Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by Borrelia burgdorferi // J Clin Invest. 2022; 132 (6): e152506.</mixed-citation><mixed-citation xml:lang="en">Gwynne P. J., Clendenen L. H., Turk S. P., et al. Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by Borrelia burgdorferi // J Clin Invest. 2022; 132 (6): e152506.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuura E., Igarashi Y., Fujimoto M., et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease // Lancet. 1990; 336: 177-178.</mixed-citation><mixed-citation xml:lang="en">Matsuura E., Igarashi Y., Fujimoto M., et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease // Lancet. 1990; 336: 177-178.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Abdel-Wahab N., Lopez-Olivo M. A., PintoPatarroyo G. P., Suarez-Almazor M. E. Systematic review of case reports of antiphospholipid syndrome following infection // Lupus. 2016; 25 (14): 1520-1531.</mixed-citation><mixed-citation xml:lang="en">Abdel-Wahab N., Lopez-Olivo M. A., PintoPatarroyo G. P., Suarez-Almazor M. E. Systematic review of case reports of antiphospholipid syndrome following infection // Lupus. 2016; 25 (14): 1520-1531.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Noakes D., Evans K., Pathansali R. The return of a former foe: syphilis with antiphospholipid syndrome as a cause of acute stroke // JRSM Open. 2017; 8 (9): 2054270417725498.</mixed-citation><mixed-citation xml:lang="en">Noakes D., Evans K., Pathansali R. The return of a former foe: syphilis with antiphospholipid syndrome as a cause of acute stroke // JRSM Open. 2017; 8 (9): 2054270417725498.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ruffatti A., Olivieri S., Tonello M., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification // J Thromb Haemost. 2008; 6: 1693-1696.</mixed-citation><mixed-citation xml:lang="en">Ruffatti A., Olivieri S., Tonello M., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification // J Thromb Haemost. 2008; 6: 1693-1696.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Praprotnik S., Ferluga D., Vizjak A., et al. Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome // Clin Rev Allergy Immunol. 2009; 36 (2-3): 109-125.</mixed-citation><mixed-citation xml:lang="en">Praprotnik S., Ferluga D., Vizjak A., et al. Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome // Clin Rev Allergy Immunol. 2009; 36 (2-3): 109-125.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gao K., Shen X., Lin Y., et al. Origin of Nontreponemal Antibodies During Treponema pallidum Infection: Evidence From a Rabbit Model // J Infect Dis. 2018; 218 (5): 835-843.</mixed-citation><mixed-citation xml:lang="en">Gao K., Shen X., Lin Y., et al. Origin of Nontreponemal Antibodies During Treponema pallidum Infection: Evidence From a Rabbit Model // J Infect Dis. 2018; 218 (5): 835-843.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Решетняк Т. М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция) // Научно-практическая ревматология. 2014; 52 (1): 56-71.</mixed-citation><mixed-citation xml:lang="en">Reshetnyak T. M. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture) // Rheumatology Science and Practice. 2014; 52 (1): 56-71.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Vandevelde A., Devreese K. M. J. Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances // J Clin Med. 2022; 11 (8): 2164.</mixed-citation><mixed-citation xml:lang="en">Vandevelde A., Devreese K. M. J. Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances // J Clin Med. 2022; 11 (8): 2164.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
